Wellington Management Group LLP Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Wellington Management Group LLP significantly reduced its stake in Regeneron Pharmaceuticals by 88.3%, selling 131,415 shares during the first quarter, leaving the fund with 17,414 shares valued at approximately $11 million.
• Regeneron recently reported a strong earnings performance, with an EPS of $12.89 for the quarter, surpassing analysts' expectations of $8.43 and achieving a 3.6% revenue increase from the previous year.
• The company announced a quarterly dividend of $0.88 per share, set to be paid on September 3rd, with a yield of 0.6% and a payout ratio of 8.87%.

Wellington Management Group LLP reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 88.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,414 shares of the biopharmaceutical company's stock after selling 131,415 shares during the period. Wellington Management Group LLP's holdings in Regeneron Pharmaceuticals were worth $11,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $27,000. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $32,000. Finally, Curat Global LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.1%

Shares of REGN stock opened at $586.96 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,210.97. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock's 50-day moving average price is $554.52 and its 200-day moving average price is $589.43. The stock has a market capitalization of $62.21 billion, a price-to-earnings ratio of 14.79, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the previous year, the firm posted $11.56 earnings per share. The business's revenue was up 3.6% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on REGN shares. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Canaccord Genuity Group reissued a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Finally, Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.